Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$129.48 +0.2%	$119.38	$73.04 ▼ $129.65	$8.36B	0.89	2.29 million shs	2.98 million shs
MIRM Mirum Pharmaceuticals	$51.93 -1.5%	$48.15	$36.20 ▼ $54.78	$2.57B	0.97	452,388 shs	255,993 shs
ROIV Roivant Sciences	$11.44 -1.8%	$11.14	$8.73 ▼ $13.06	$7.78B	1.15	6.01 million shs	4.92 million shs
RVMD Revolution Medicines	$38.30 -1.9%	$39.16	$29.17 ▼ $62.40	$7.13B	1.06	1.87 million shs	2.14 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	+0.14%	+0.10%	+0.96%	+52.98%	+13.20%
MIRM Mirum Pharmaceuticals	-0.13%	-0.53%	+4.00%	+34.86%	+37.43%
ROIV Roivant Sciences	+0.95%	+0.69%	+4.86%	+14.78%	+3.56%
RVMD Revolution Medicines	+1.69%	+1.43%	-0.23%	+6.23%	-15.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	1.0841 of 5 stars	2.1	2.0	0.0	2.3	0.8	0.6
MIRM Mirum Pharmaceuticals	3.7687 of 5 stars	3.6	0.0	4.2	2.5	1.7	0.6
ROIV Roivant Sciences	2.6712 of 5 stars	3.6	3.0	0.0	2.3	2.5	0.0
RVMD Revolution Medicines	4.5564 of 5 stars	4.5	3.0	4.7	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.24	Hold	$128.25	-0.95% Downside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	26.13% Upside
ROIV Roivant Sciences	3.25	Buy	$16.50	44.23% Upside
RVMD Revolution Medicines	3.00	Buy	$68.91	79.92% Upside

Current Analyst Ratings Breakdown

Latest MIRM, ROIV, RVMD, and BPMC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	RVMD Revolution Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00
7/11/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/10/2025	ROIV Roivant Sciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$19.00
6/25/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/24/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00 ➝ $73.00
6/24/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00
6/18/2025	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$508.82M	16.43	N/A	N/A	$4.70 per share	27.55
MIRM Mirum Pharmaceuticals	$336.89M	7.63	N/A	N/A	$4.70 per share	11.05
ROIV Roivant Sciences	$29.05M	267.71	N/A	N/A	$7.45 per share	1.54
RVMD Revolution Medicines	$11.58M	616.07	N/A	N/A	$13.47 per share	2.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	199.20	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
ROIV Roivant Sciences	-$171.98M	-$0.25	N/A	N/A	N/A	-225.71%	-14.76%	-13.69%	8/6/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.00	N/A	N/A	N/A	N/A	-37.06%	-32.84%	8/6/2025 (Estimated)

Latest MIRM, ROIV, RVMD, and BPMC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2026	ROIV Roivant Sciences	-$0.23	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	BPMC Blueprint Medicines	-$0.54	N/A	N/A	N/A	$171.34 million	N/A
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	N/A	N/A	N/A	$107.91 million	N/A
8/6/2025	Q2 2025	RVMD Revolution Medicines	-$1.14	N/A	N/A	N/A	$0.50 million	N/A
5/29/2025	Q4 2025	ROIV Roivant Sciences	-$0.16	-$0.31	-$0.15	-$0.29	$62.17 million	$7.57 million
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.01	2.80	2.75
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
ROIV Roivant Sciences	N/A	33.47	33.47
RVMD Revolution Medicines	N/A	13.46	13.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
MIRM Mirum Pharmaceuticals	N/A
ROIV Roivant Sciences	64.76%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
MIRM Mirum Pharmaceuticals	14.36%
ROIV Roivant Sciences	7.90%
RVMD Revolution Medicines	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.53 million	42.42 million	Optionable
ROIV Roivant Sciences	860	679.81 million	626.10 million	Optionable
RVMD Revolution Medicines	250	186.27 million	170.99 million	Optionable

MIRM, ROIV, RVMD, and BPMC Headlines

Recent News About These Companies

Bank of New York Mellon Corp Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

July 18 at 3:25 AM | marketbeat.com

Goldman Sachs Initiates Coverage of Revolution Medicines (RVMD) with Buy Recommendation

July 15 at 10:01 PM | msn.com

Revolution Medicines (NASDAQ:RVMD) Now Covered by Analysts at The Goldman Sachs Group

July 15 at 8:41 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Edgestream Partners L.P.

July 14, 2025 | marketbeat.com

Revolution Medicines and Iambic Announce Technology and Research ...

July 11, 2025 | nasdaq.com

Revolution Medicines and Iambic Therapeutics Announce ... - Nasdaq

July 11, 2025 | nasdaq.com

Iambic and Revolution Medicines Partner on AI Cancer Drug Discovery

July 9, 2025 | genengnews.comG

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

July 9, 2025 | finance.yahoo.com

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates

July 9, 2025 | globenewswire.com

Allspring Global Investments Holdings LLC Trims Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

July 9, 2025 | marketbeat.com

China Universal Asset Management Co. Ltd. Acquires 27,982 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

July 8, 2025 | marketbeat.com

Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors

July 6, 2025 | msn.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Position Boosted by WCM Investment Management LLC

July 3, 2025 | marketbeat.com

Revolution Medicines and Summit Therapeutics Announce Clinical Collaboration to Evaluate RAS (ON) Inhibitors in Combination with Ivonescimab for Solid Tumors - Nasdaq

July 2, 2025 | nasdaq.com

Leerink Partnrs Issues Optimistic Estimate for RVMD Earnings

July 2, 2025 | marketbeat.com

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

June 30, 2025 | globenewswire.com

Lunate Capital Ltd Invests $77.66 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

June 29, 2025 | marketbeat.com

Q3 EPS Estimate for Revolution Medicines Raised by Analyst

June 27, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by Analysts

June 26, 2025 | marketbeat.com

Revolution Medicines' (RVMD) Buy Rating Reiterated at Guggenheim

June 25, 2025 | marketbeat.com

Wedbush Reiterates "Outperform" Rating for Revolution Medicines (NASDAQ:RVMD)

June 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRM, ROIV, RVMD, and BPMC Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$129.48 +0.20 (+0.15%)

Closing price 07/17/2025 05:56 PM Eastern

Extended Trading

$129.48 0.00 (0.00%)

As of 07/17/2025 05:56 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Mirum Pharmaceuticals NASDAQ:MIRM

$51.93 -0.80 (-1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$51.92 -0.02 (-0.03%)

As of 04:20 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Roivant Sciences NASDAQ:ROIV

$11.44 -0.21 (-1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$11.42 -0.01 (-0.13%)

As of 04:32 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Revolution Medicines NASDAQ:RVMD

$38.30 -0.75 (-1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$38.30 0.00 (0.00%)

As of 04:20 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time